Relador Pak
NDC Package 69166-155-90

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Relador Pak is lidocaine 2.5% and prilocaine 2.5% cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on:      normal intact skin for local analgesia. Marketed by Accelis Pharma, this product is identified by NDC 69166-155 and is authorized under FDA application ANDA076290.

Identification & Billing

NDC Package Code
69166-155-90
Package Description
1 KIT in 1 CARTON * 1 TUBE in 1 CARTON (50383-667-30) / 30 g in 1 TUBE * 1 in 1 PACKAGE
Product Code
69166-155
11-Digit Billing Format
69166015590
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
RxNorm Crosswalk
  • RxCUI: 1656327 - Relador Pak 2.5 % / 2.5 % Topical Cream
  • RxCUI: 1656327 - lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream [Relador]
  • RxCUI: 197877 - lidocaine 2.5 % / prilocaine 2.5 % Topical Cream
  • RxCUI: 197877 - lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream

Clinical Specifications

Proprietary Name
Relador Pak Plus
Dosage Form
-
Usage Information
Lidocaine 2.5% and prilocaine 2.5% cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on:      normal intact skin for local analgesia.       genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.Lidocaine 2.5% and prilocaine 2.5% cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies (see WARNINGS).

Regulatory & Marketing

Labeler Name
Accelis Pharma
FDA Application #
ANDA076290
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-25-2015
Listing Expiration
12-31-2019
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69166-155-90 identifies a specific commercial package of 1 kit in 1 carton * 1 tube in 1 carton (50383-667-30) / 30 g in 1 tube * 1 in 1 package of Relador Pak Plus, labeled by Accelis Pharma. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Accelis Pharma on April 25, 2015. The current certification is valid through December 31, 2019.

How is this Accelis Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69166015590. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69166-155-90
11-Digit CMS (5-4-2)
69166-0155-90

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.